Skip to main content
BrightStudy

Clinical research directory

Find Clinical Research Opportunities That May Fit

Answer a few questions to explore currently recruiting studies. Some studies may offer compensation for participants' time and travel.

See possible matchesHow it works
  • No cost to search
  • Participation is voluntary
  • Final eligibility is determined by study staff

Compensation, eligibility and study availability vary. Submitting your information does not guarantee qualification, enrollment, medical treatment or payment.

A woman reading on a tablet at a table in a bright room

How it works

Tell us what types of research interest you

A few broad questions — your ZIP code, an age confirmation and a general area of interest. We do not ask for diagnoses or medical records.

Review possible currently recruiting studies

We show listings sourced from ClinicalTrials.gov, with the NCT number, sponsor, locations and a link to the original record so you can read it yourself.

A study team determines final eligibility

If you ask to be connected, the research site reviews your situation and decides. BrightStudy never makes eligibility or enrollment decisions.

Participation is always optional

You can stop at any point, unsubscribe from emails immediately, or ask us to delete your information.

Current opportunities

Public directory listings sourced from ClinicalTrials.gov. Only studies with a recruiting status are shown, and listings that stop recruiting are removed on the next refresh.

Browse all listings
Recruiting
Public directory listing
NCT05672927

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Listed focus: Immunization, HPV Infection, Human Papillomavirus

The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose…

Basic eligibility summary
Ages 27 Years to 45 Years · female participants · accepts healthy volunteers
Locations
Galveston, Texas
Eligibility summary from the record

1. Females 27-45 years old. 2. Ability to give informed consent. 3. Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record. 4. Reliable telephone access for the duration of the project. 5. Can read and…

Summarized from the sponsor's posted criteria. The research site makes the final eligibility decision.

Sponsor / responsible party: The University of Texas Medical Branch, Galveston

Source: ClinicalTrials.gov · Record updated September 10, 2026 · Last checked by BrightStudy September 15, 2026

Compensation is not stated for this listing. BrightStudy does not add compensation information unless it is independently verified with the study partner.

View the full record on ClinicalTrials.gov
Recruiting
Public directory listing
NCT07748403

A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)

Listed focus: Wilson Disease, Wilson's Disease, Wilsons Disease

The purpose of this study is to evaluate the safety, tolerability, biological activity, and initial efficacy of PM577a, an investigational Prime Editing therapy, in adults and adolescents with Wilson disease (WD). Wilson disease is caused by changes (mutations) in the ATP7B gene that prevent the body from removing excess copper normally…

Basic eligibility summary
Ages 12 Years
Locations
Chicago, Illinois · San Antonio, Texas
Eligibility summary from the record

* Confirmed Wilson Disease (WD) diagnosis as determined by medical history consistent with WD * Historical genetic analysis demonstrating biallelic pathogenic, likely pathogenic, or suspected pathogenic ATP7B variants, including at least one p.H1069Q allele. * Treated and stable on standard of care therapy for WD for…

Summarized from the sponsor's posted criteria. The research site makes the final eligibility decision.

Sponsor / responsible party: Prime Medicine, Inc.

Source: ClinicalTrials.gov · Record updated September 11, 2026 · Last checked by BrightStudy September 15, 2026

Compensation is not stated for this listing. BrightStudy does not add compensation information unless it is independently verified with the study partner.

View the full record on ClinicalTrials.gov
Recruiting
Public directory listing
NCT05626114

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

Listed focus: Geographic Atrophy

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated. The substudy will evaluate the…

Basic eligibility summary
Ages 50 Years
Locations
Beverly Hills, California · Sacramento, California · San Francisco, California · +12 more
Eligibility summary from the record

* Ability to undergo a vitreoretinal surgical procedure under monitored anesthesia care * Diagnosis of GA secondary to AMD * Best corrected visual acuity (BCVA) score ≥ 29 letters and ≤ 60 letters in the study eye as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) * Pseudophakic (study eye)

Summarized from the sponsor's posted criteria. The research site makes the final eligibility decision.

Sponsor / responsible party: Genentech, Inc.

Source: ClinicalTrials.gov · Record updated September 12, 2026 · Last checked by BrightStudy September 15, 2026

Compensation is not stated for this listing. BrightStudy does not add compensation information unless it is independently verified with the study partner.

View the full record on ClinicalTrials.gov

Why BrightStudy

No cost to search

BrightStudy is free for participants. We never ask you to pay to view a listing or to be referred to a study site.

Clear privacy choices

Email consent is separate and never pre-checked. Your answers are never sent to advertising pixels, analytics platforms or session-replay tools.

Participation is voluntary

Expressing interest is not an application. You are free to decline any study at any stage, including after speaking with a research site.

Direct access to sourced study information

Every public listing links to its ClinicalTrials.gov record and shows when we last checked it, so you can verify what you read.

Frequently asked questions

See what research is recruiting near you

It takes about a minute, costs nothing, and does not commit you to anything. A study team always makes the final eligibility decision.

See possible matches

Compensation, eligibility and study availability vary. Submitting your information does not guarantee qualification, enrollment, medical treatment or payment. BrightStudy is operated by Easy Benefits Help LLC, a Wyoming limited liability company.